Penrod

MARCH 7, 2024

Digital patient forms offer a superior solution for the healthcare sector, swiftly supplanting traditional paperwork. The level of detail needed makes the task tedious for most patients. Effective communication is vital when it comes to providing the best patient care. Safeguarding patient data is crucial.

Healthcare 52

Healthcare Healthcare Patients Leads 52

PM360

FEBRUARY 23, 2024

The team worked directly with the MG patient community to build a clean story, then the team embraced an educational yet youthful film style.

Education 52

Education Pharma Leads Marketing 52

PM360

FEBRUARY 12, 2024

Created by The European Organization for Rare Diseases (EURORDIS) , this globally coordinated event brings together industry stakeholders to advocate for increased access to medical treatment for patients, caregivers, and their families.

Food and Drug Administration 105

Food and Drug Administration Patients Networking Medical 105

PM360

JUNE 23, 2023

Press Release Contact: Kayla Walsh Awards Coordinator, PM360 646-300-8114 kayla.walsh@pm360online.com PM360 Now Accepting Entries for 2024 Pharma Choice Awards Call for the Best Healthcare Creative from the Past Year NEW YORK, NY, June 22, 2023 : The 2024 PM360 Pharma Choice Awards are officially open for entries.

Pharma 52

Pharma Marketing Healthcare Healthcare 52

PM360

FEBRUARY 8, 2024

The campaign helped showcase the ability of VNS patients to experience improved quality of life by illustrating everyday activities. VNS Therapy is a Life-changer VNS (vagus nerve stimulation) Therapy is designed for people living with seizures despite trying multiple medications.

Pharma 52

Pharma Sales Management Healthcare 52

European Pharmaceutical Review

APRIL 17, 2024

Roche’s twice-yearly, 10-minute subcutaneous injection of OCREVUS ® (ocrelizumab) has shown significant promise for patients with either with relapsing or primary progressive multiple sclerosis (RMS or PPMS). percent had no relapse) in patients through 48 weeks of the treatment. No new safety signals were identified for OCREVUS SC.

Food and Drug Administration 66

Food and Drug Administration Safety Medicine Food 66

PM360

FEBRUARY 8, 2024

It provides an easier experience for HCPs to navigate between critical data and resources when making important treatment decisions for patients with HR+/HER2- mBC.seizure control. This streamlined website experience features the LIFE campaign and brings this idea front and center.

Pharma 52

Pharma Management Leads Medical 52

Clarivate

MAY 14, 2024

While initially developed to help regulate blood sugar levels, they have also been found to promote appetite suppression, leading to weight loss in patients. What’s leading to the boom in development of semaglutide biosimilars? Per recent Clarivate estimates, the therapeutic market for these drugs is valued at approximately $1.7

Manufacturing 52

Manufacturing Marketing Leads Medicine 52

European Pharmaceutical Review

NOVEMBER 21, 2023

Phase III trials of a low carbon version of GSK’s metered dose inhaler, Ventolin (salbutamol), using a next generation, lower carbon propellant, are set to start in 2024. According to GSK, thirty-five million patients with respiratory conditions globally relying on its metered dose inhaler.

Manufacturing 106

Manufacturing Patients Pharma Leads 106

Clarivate

MAY 1, 2024

We took a look at these drugs’ impact on the medtech sector for our forthcoming report, Medtech Trends to Watch in 2024 , and found a more nuanced picture. These drugs could also enlarge the pool of candidates for major joint surgeries as patients become more physically active after achieving weight reductions, as Stryker has noted.

Side effects 59

Side effects Physicians Medical Patients 59

European Pharmaceutical Review

APRIL 2, 2024

Wienand will join the contract development and manufacturing organisation (CDMO) in the summer of 2024. Together, we will enable a healthier world for patients in need”. Wolfgang Wienand has been chosen to succeed Albert Baehny as the CEO of Lonza. He has been CEO of the Swiss CDMO Siegfried Holding AG since 2019. billion.

Biopharma 79

Biopharma Leads Manufacturing Pharmaceutical 79

PM360

MARCH 22, 2024

Exploring the role of patient advocacy groups and clinical trials while discussing the challenges faced, and how artificial intelligence and modern methods revolutionize the landscape. As a result, newly diagnosed families frequently rely on patient advocacy groups (PAGs) for up-to-date information.

Patients 52

Patients Recruitment Ethics Government 52

pharmaphorum

SEPTEMBER 29, 2022

A digital patient monitoring tool developed by UK company CyberLiver has been given a breakthrough designation by the FDA for out-of-hospital management of patients with cirrhosis at risk of complications. The post Digital tool cuts hospital readmissions in cirrhosis patients appeared first on.

Patients 52

Patients Management Consulting FDA 52

European Pharmaceutical Review

MARCH 5, 2024

The company highlighted that 35 percent of patients enrolled in its clinical trials are based in Europe. The company stated that de la Rocha transitioned to the role of Head of Clinical Operations, Europe, in early 2024. BeiGene has appointed Pilar de la Rocha as its new Head of Europe, Global Clinical Operations.

Medicine 90

Medicine Leads Medical Manufacturing 90

European Pharmaceutical Review

MARCH 18, 2024

A Phase III trial has shown that compared oral drug delivery, administering levodopa through an infusion pump led to nearly two hours of day (1.72) of additional time in which the medicine reduced symptoms in Parkinson’s patients. There were 381 Parkinson’s patients enrolled in the trial. and Joan A.

Food and Drug Administration 87

Food and Drug Administration Medicine Physicians Food 87

European Pharmaceutical Review

FEBRUARY 14, 2024

Gilead confirmed that CymaBay’s lead product candidate seladelpar has a best-in-disease profile for second-line primary biliary cholangitis (PBC). percent for patients on seladelpar versus 20.0 percent for patients on seladelpar versus 0.0 Gilead Sciences has agreed to acquire CymaBay Therapeutics for a total equity value of $4.3

Transportation 77

Transportation Patients Pharma Leads 77

European Pharmaceutical Review

DECEMBER 22, 2023

The deal includes Karuna’s lead asset KarXT (xanomeline-trospium), a potential first-in-class treatment for schizophrenia. Currently under review by the US Food and Drug Administration (FDA), KarXT is expected to launch in the US in late 2024. per share in cash.

Food and Drug Administration 92

Food and Drug Administration Side effects Safety Food 92

European Pharmaceutical Review

APRIL 15, 2024

Positive data from MaaT Pharma’s Microbiome Ecosystem Therapy TM (MET) MaaT013 as a treatment for acute graft-versus-host disease (aGvHD), is set to be presented at the 2024 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting. This data summary is based on an abstract from the Annual Meeting.

Pharma 85

Pharma Patients Management Leads 85

PM360

DECEMBER 12, 2023

The initial deadline for submissions is February 23, 2024. PM360 will then continue to accept entries until March 15, 2024, but anything after Feb. PM360 will then continue to accept entries until March 15, 2024, but anything after Feb. 23 will be subject to a $200 late fee. 23 will be subject to a $200 late fee.

Education 52

Education Healthcare Healthcare Marketing 52

Pharmaceutical Technology

JUNE 6, 2023

Findings from a two-year placebo-controlled, double-blind Phase II trial showed that Stargardt patients treated with gildeuretinol once a day as a pill experienced a statistically and clinically meaningful slowing of retinal damage over placebo. Alkeus Pharmaceuticals intends to submit a new drug application for gildeuretinol in 2024.

Food and Drug Administration 111

Food and Drug Administration Food Pharmaceutical Medicine 111

European Pharmaceutical Review

APRIL 24, 2024

New trial data for a gene therapy presented at the International Myology 2024 Congress has revealed “good” tolerability in Duchenne muscular dystrophy, when combined with transient immunological prophylactic treatment, as well as efficacy data relating to microdystrophin expression and functional improvement. Specifically, a Spc5.11

Patients 52

Patients Leads Pharmaceutical 52

European Pharmaceutical Review

DECEMBER 5, 2023

Carmot Therapeutics’ lead asset CT-388 is a Phase-II ready dual GLP-1/GIP agonist with best-in-class potential as a treatment for obesity in individuals with and without type 2 diabetes. The closing of the transaction is currently expected to occur in the first quarter of 2024.

Food 90

Food Leads Pharma Patients 90

European Pharmaceutical Review

JANUARY 18, 2024

Cell and Gene Therapy Catapult opens new laboratories Leading Europe’s cell and gene therapy sector According to a new report from the UK BioIndustry Association (BIA) in collaboration with Citeline, the UK is making significant moves to affirm its leading position within the cell and gene therapy (CGT) sector.

Distribution 95

Distribution Manufacturing Medicine Government 95

European Pharmaceutical Review

NOVEMBER 28, 2023

According to the FDA, this clinical trial evaluated 142 adult patients with progressing desmoid tumours not suitable to surgery. Patients were randomised to receive 150mg of Ogsiveo or placebo. A response rate of 41 percent was observed in the Ogsiveo arm, while this rate was eight percent in the placebo arm.

Food and Drug Administration 80

Food and Drug Administration Medicine FDA Food 80

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.

Food and Drug Administration 92

Food and Drug Administration Side effects Leads Patients 92

European Pharmaceutical Review

MARCH 14, 2024

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.

Food and Drug Administration 91

Food and Drug Administration Side effects Leads Patients 91

European Pharmaceutical Review

APRIL 2, 2024

At Roche, we see it as our ethical and environmental responsibility to support the use of alternative methods that prioritise animal welfare while ensuring the safety of our patients and the quality of our products. in the monographs for Water for Injection (0169) and Purified Water (0008) on 1 April 2024. on 1 January 2024.

Ethics 86

Ethics Manufacturing Marketing Networking 86

PM360

FEBRUARY 8, 2024

leading technology provider for modern clinical trials, is using a new intelligent automation technology to provide faster build of standard trial timelines. Medable’s updated eCOA includes an auto-configuration tool that produces standard configurations, such as schedules of assessments, anchor dates, and patient flags, in minutes.

Media 52

Media Electronics Patients Healthcare 52

World of DTC Marketing

DECEMBER 4, 2020

SUMMARY: McKinsey estimates that global digital-health revenues—from telemedicine, online pharmacies, wearable devices, and so on—will rise from $350bn last year to $600bn in 2024. Some 70% of American hospitals still fax and post patient records, and patients don’t have one record to share among all their doctors.

Medicine 201

Medicine Doctors Medical Media 201

PM360

SEPTEMBER 21, 2023

This article covers some of the reasons these drugs were chosen, how the process for price negotiation will occur, and the impact for the industry and for patients. Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

PharmaTimes

DECEMBER 19, 2023

Immunotherapies that target T cells have already proved highly effective for patients living with cancer. However, many patients remain resistant to them. We believe that the research team established through this collaboration will lead to the discovery of the next generation of immunotherapy.”

Pharmaceutical 75

Pharmaceutical Management Leads Patients 75

European Pharmaceutical Review

FEBRUARY 2, 2024

The ATLab (Alpha Therapy Laboratory) Valenciennes in Onnaing, France, will produce lead-212 radioligand therapies. So construction of the new radioligand therapy manufacturing site in France is a major step towards making these promising new treatments available to cancer patients with high unmet needs.

Manufacturing 83

Manufacturing Distribution Leads Pharmaceutical 83

European Pharmaceutical Review

NOVEMBER 17, 2023

The European Commission has approved Ebglyss (lebrikizumab) for atopic dermatitis patients 12 years and older with a body weight of at least 40kg, who are candidates for systemic therapy. The company said it will launch lebrikizumab in Germany, with further European rollout planned throughout 2024.

Safety 79

Safety Patients Management Leads 79

European Pharmaceutical Review

AUGUST 24, 2023

.” “… compared to the capsules currently in use in the 201 clinical trial, the smaller tablets may overcome challenges patients have swallowing oral medication as a result of their disease. In the company’s Phase II 201 trial , three doses of IkT 148009 were evaluated for safety in patients with untreated Parkinson’s disease.

Safety 85

Safety Medical Medicine Patients 85

European Pharmaceutical Review

JANUARY 24, 2024

percent for placebo)” What the Phase IIIb study of Tremfya found The topline data from Cohort B of the Phase IIIb VISIBLE study presented at the Maui Derm Hawaii 2024 conference, showed that at Week 16, after three doses of Tremfya, patients achieved significantly greater improvements versus placebo. percent compared to 37.8

Medicine 75

Medicine Prospecting Patients Leads 75

Pharmaceutical Technology

SEPTEMBER 6, 2022

The US Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Avacta Group’s lead pre|CISION drug candidate, AVA6000, to treat soft tissue sarcoma. By 2024, doxorubicin is anticipated to have a market size of $1.38bn and is extensively utilised as a part of the standard of care in various types of cancers. .

Food and Drug Administration 98

Food and Drug Administration FDA Safety Food 98

pharmaphorum

SEPTEMBER 6, 2022

Pleco Therapeutics has closed a first-round financing, raising just over €17 million that it says will fund the development of its lead therapy for acute myeloid leukaemia (AML) through to regulatory filings in the US and EU. The Series A round includes €3.6

Leads 88

Leads Biopharma Government Patients 88